Literature DB >> 14618263

Multiple flavonoid-binding sites within multidrug resistance protein MRP1.

D Trompier1, H Baubichon-Cortay, X-B Chang, M Maitrejean, D Barron, J R Riordon, A Di Pietro.   

Abstract

Recombinant nucleotide-binding domains (NBDs) from human multidrug resistance protein MRP1 were overexpressed in bacteria and purified to measure their direct interaction with high-affinity flavonoids, and to evaluate a potential correlation with inhibition of MRP1-mediated transport activity and reversion of cellular multidrug resistance. Among different classes of flavonoids, dehydrosilybin exhibited the highest affinity for both NBDs, the binding to N-terminal NBD1 being prevented by ATP. Dehydrosilybin increased vanadate-induced 8-N3-[alpha-32P]ADP trapping, indicating stimulation of ATPase activity. In contrast, dehydrosilybin strongly inhibited leukotriene C4 (LTC4) transport by membrane vesicles from MRP1-transfected cells, independently of reduced glutathione, and chemosensitized cell growth to vincristine. Hydrophobic C-isoprenylation of dehydrosilybin increased the binding affinity for NBD1, but outsite the ATP site, lowered the increase in vanadate-induced 8-N3-[alpha-32P]ADP trapping, weakened inhibition of LTC4 transport which became glutathione dependent, and induced some cross-resistance. The overall results indicate multiple binding sites for dehydrosilybin and its derivatives, on both cytosolic and transmembrane domains of MRP1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618263     DOI: 10.1007/s00018-003-3177-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  22 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

2.  Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.

Authors:  Paulus Kirchhof; Thomas Fetsch; Peter Hanrath; Thomas Meinertz; Gerhard Steinbeck; Walter Lehmacher; Günter Breithardt
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

3.  Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.

Authors:  Ali El-Armouche; Peter Boknik; Thomas Eschenhagen; Lucie Carrier; Michael Knaut; Ursula Ravens; Dobromir Dobrev
Journal:  Circulation       Date:  2006-08-07       Impact factor: 29.690

4.  Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Douglas Packer; Allan Skanes
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

5.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann
Journal:  Eur Heart J       Date:  2006-08       Impact factor: 29.983

6.  Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique.

Authors:  Feifan Ouyang; Matthias Antz; Sabine Ernst; Hitoshi Hachiya; Hercules Mavrakis; Florian T Deger; Anselm Schaumann; Julian Chun; Peter Falk; Detlef Hennig; Xingpeng Liu; Dietmar Bänsch; Karl-Heinz Kuck
Journal:  Circulation       Date:  2004-12-27       Impact factor: 29.690

7.  Increased atrial fibrillation mortality: United States, 1980-1998.

Authors:  Wendy A Wattigney; George A Mensah; Janet B Croft
Journal:  Am J Epidemiol       Date:  2002-05-01       Impact factor: 4.897

8.  Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design.

Authors:  Andreas Goette; Günter Breithardt; Thomas Fetsch; Peter Hanrath; Helmut U Klein; Walter Lehmacher; Gerhard Steinbeck; Thomas Meinertz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation).

Authors:  Robert L McNamara; Lawrence M Brass; Joseph P Drozda; Alan S Go; Jonathan L Halperin; Charles R Kerr; Samuel Lévy; David J Malenka; Suneet Mittal; Frank Pelosi; Yves Rosenberg; Daniel Stryer; D George Wyse; Martha J Radford; David C Goff; Frederick L Grover; Paul A Heidenreich; David J Malenka; Eric D Peterson; Rita F Redberg
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

10.  Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.

Authors:  Andreas Goette; Alicja Bukowska; Uwe Lendeckel; Michaela Erxleben; Matthias Hammwöhner; Denis Strugala; Jan Pfeiffenberger; Friedrich-Wilhelm Röhl; Christof Huth; Matthias P A Ebert; Helmut U Klein; Christoph Röcken
Journal:  Circulation       Date:  2008-01-28       Impact factor: 29.690

View more
  8 in total

1.  Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5).

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Stephen B Hladky; Suresh V Ambudkar; Margery A Barrand
Journal:  FEBS J       Date:  2005-09       Impact factor: 5.542

2.  Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.

Authors:  José M Pérez-Victoria; Fernando Cortés-Selva; Adriana Parodi-Talice; Boris I Bavchvarov; F Javier Pérez-Victoria; Francisco Muñoz-Martínez; Mathias Maitrejean; M Paola Costi; Denis Barron; Attilio Di Pietro; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.

Authors:  Rui Zhang; Li Chen; Sarn Jiralerspong; Ann Snowden; Steven Steinberg; Nancy Braverman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

4.  Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer.

Authors:  Kanin Rungsardthong; Sergio Mares-Sámano; Jeffrey Penny
Journal:  Bioinformation       Date:  2012-10-01

5.  Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

Authors:  Michael Wink; Mohamed L Ashour; Mahmoud Zaki El-Readi
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

6.  A simple gene set-based method accurately predicts the synergy of drug pairs.

Authors:  Yu-Ching Hsu; Yu-Chiao Chiu; Yidong Chen; Tzu-Hung Hsiao; Eric Y Chuang
Journal:  BMC Syst Biol       Date:  2016-08-26

Review 7.  Molecular Pathways Involved in the Anti-Cancer Activity of Flavonols: A Focus on Myricetin and Kaempferol.

Authors:  Maria Rosa Felice; Alessandro Maugeri; Giovambattista De Sarro; Michele Navarra; Davide Barreca
Journal:  Int J Mol Sci       Date:  2022-04-16       Impact factor: 6.208

8.  Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.

Authors:  Olga Wesołowska; Andrzej B Hendrich; Barbara Łaniapietrzak; Jerzy Wiśniewski; Joseph Molnar; Imre Ocsovszki; Krystyna Michalak
Journal:  Cell Mol Biol Lett       Date:  2008-11-19       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.